In this issue of Blood, Dietrich and colleagues report disappointing results with the use of melphalan parenterally with dexamethasone in patients with immunoglobulin light chain amyloidosis. The median survival of 61 patients was 17.5 months. The 3 months all cause mortality was 28%.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Jul 29 2010|
ASJC Scopus subject areas
- Cell Biology